IP Library › Granted Patent US 12,285,432
Granted Patent B2
US 12,285,432 · App. 18/382,307 · Granted Apr 29, 2025

Treatment of hair loss disorders with deuterated JAK inhibitors

Inventors: James V. Cassella (Essex, CT); Christopher L. Brummel (Marlborough, MA)
Assignee: Sun Pharmaceutical Industries, Inc.
A61K31/519A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,432
App. No.
18/382,307
Granted
Apr 29, 2025
Kind
B2
Abstract

A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.

Claims (42)

1. A method of treating a hair loss disorder in a human subject in need thereof, the method comprising orally administering to the human subject about 4 mg to about 50 mg of Compound (I) represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein:

(i) about 0.1 mg to about 200 mg of a CYP3A4 inhibitor is being co-administered to the human subject; and

(ii) no adjustment of the dosage of Compound (I), or a pharmaceutically acceptable salt thereof, is required due to the co-administering of the CYP3A4 inhibitor,

wherein the hair loss disorder is alopecia areata, alopecia totalis or alopecia universalis.

2. The method of claim 1 , wherein the hair loss disorder is alopecia areata.

3. The method of claim 1 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered at about 16 mg/day, or about 24 mg/day, wherein the about 16 mg/day of Compound (I) or pharmaceutically acceptable salt thereof is administered as about 8 mg twice per day and the about 24 mg/day of the compound or pharmaceutically acceptable salt thereof is administered as about 12 mg twice per day.

4. The method of claim 1 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical formulation which is a tablet.

5. The method of claim 1 , wherein the human subject's SALT score is less than or equal to 20 after treatment.

6. The method of claim 1 , wherein the CYP3A4 inhibitor is a strong CYP3A4 inhibitor.

7. The method of claim 1 , wherein no interruption of the administration of the CYP3A4 inhibitor is required.

8. A method of treating a hair loss disorder in a human subject in need thereof, the method comprising orally administering to the human subject about 4 mg to about 50 mg of Compound (I) represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein:

(ii) the subject is receiving a concomitant administration of about 0.1 mg to about 200 mg of a CYP3A4 inhibitor; and

(ii) the amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor, wherein the hair loss disorder is alopecia areata, alopecia totalis or alopecia universalis.

9. The method of claim 8 , wherein the hair loss disorder is alopecia areata.

10. The method of claim 8 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered at about 16 mg/day, or about 24 mg/day, wherein the about 16 mg/day of Compound (I) or pharmaceutically acceptable salt thereof is administered as about 8 mg twice per day and the about 24 mg/day of the compound or pharmaceutically acceptable salt thereof is administered as about 12 mg twice per day.

11. The method of claim 8 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical formulation which is a tablet.

12. The method of claim 8 , wherein the human subject's SALT score is less than or equal to 20 after treatment.

13. The method of claim 8 , wherein the CYP3A4 inhibitor is a strong CYP3A4 inhibitor.

14. The method of claim 8 , wherein no interruption of the administration of the CYP3A4 inhibitor is required.

15. A method of treating a hair loss disorder in a human subject in need thereof, the method comprising orally administering to the human subject about 4 mg to about 50 mg of Compound (I) represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein:

(i) the subject has been determined to be receiving a concomitant administration of about 0.1 mg to about 200 mg of a CYP3A4 inhibitor; and

(ii) the amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor, wherein the hair loss disorder is alopecia areata, alopecia totalis or alopecia universalis.

16. The method of claim 15 , wherein the hair loss disorder is alopecia areata.

17. The method of claim 15 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered at about 16 mg/day, or about 24 mg/day, wherein the about 16 mg/day of Compound (I) or pharmaceutically acceptable salt thereof is administered as about 8 mg twice per day and the about 24 mg/day of the compound or pharmaceutically acceptable salt thereof is administered as about 12 mg twice per day.

18. The method of claim 15 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical formulation which is a tablet.

19. The method of claim 15 , wherein the human subject's SALT score is less than or equal to 20 after treatment.

20. The method of claim 15 , wherein the CYP3A4 inhibitor is a strong CYP3A4 inhibitor.

21. The method of claim 15 , wherein no interruption of the administration of the CYP3A4 inhibitor is required.

22. A method of treating a hair loss disorder in a human subject in need thereof, the method comprising:

(iii) determining if the human subject is receiving a concomitant administration of a CYP3A4 inhibitor; and

(iv) orally administering to the human subject about 4 mg to about 50 mg of Compound (I) if the subject is receiving concomitant administration of about 0.1 mg to about 200 mg of a CYP3A4 inhibitor, wherein Compound (I) is represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and

wherein, the amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor, wherein the hair loss disorder is alopecia areata, alopecia totalis or alopecia universalis.

23. The method of claim 22 , wherein the hair loss disorder is alopecia areata.

24. The method of claim 22 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered at about 16 mg/day, or about 24 mg/day, wherein the about 16 mg/day of Compound (I) or pharmaceutically acceptable salt thereof is administered as about 8 mg twice per day and the about 24 mg/day of the compound or pharmaceutically acceptable salt thereof is administered as about 12 mg twice per day.

25. The method of claim 22 , wherein Compound (I), or a pharmaceutically acceptable salt thereof, is administered in a pharmaceutical formulation which is a tablet.

26. The method of claim 22 , wherein the human subject's SALT score is less than or equal to 20 after treatment.

27. The method of claim 22 , wherein the CYP3A4 inhibitor is a strong CYP3A4 inhibitor.

28. The method of claim 22 , wherein no interruption of the administration of the CYP3A4 inhibitor is required.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2023
From: CASSELLA, JAMES V.; BRUMMEL, CHRISTOPHER L.
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 065305/0546 →
MERGER Recorded Oct 23, 2023
From: CONCERT PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 065305/0564 →
Continuity (3)
Continuation PCTUS2022040115 · Aug 11, 2022
Provisional Application 63232107 · Aug 11, 2021
Related Publication 20240058345A1 · Feb 22, 2024
References Cited (59)
US 7598257B2 · Rodgers et al. · 2009 [cited by applicant]
US 9198911B2 · Christiano et al. · 2015 [cited by applicant]
US 9249149B2 · Silverman et al. · 2016 [cited by applicant]
US 9662335B2 · Rodgers et al. · 2017 [cited by applicant]
US 10265258B2 · Christiano et al. · 2019 [cited by applicant]
US 10561659B2 · Wagner et al. · 2020 [cited by applicant]
US 11298570B2 · Christiano et al. · 2022 [cited by applicant]
US 20070135461A1 · Rodgers et al. · 2007 [cited by applicant]
US 20080312258A1 · Rodgers et al. · 2008 [cited by applicant]
US 20140135350A1 · Ni et al. · 2014 [cited by applicant]
US 20150197525A1 · Silverman et al. · 2015 [cited by applicant]
US 20150239896A1 · Silverman et al. · 2015 [cited by applicant]
WO WO2007065167A1 · 2007 [cited by examiner]
WO WO2012061537A2 · 2012 [cited by applicant]
WO WO2013149194A1 · 2013 [cited by applicant]
WO WO2014078486A1 · 2014 [cited by applicant]
WO WO2015120110A2 · 2015 [cited by applicant]
WO WO2017192905A1 · 2017 [cited by applicant]
WO WO2023018904 · 2023 [cited by applicant]
Anonymous, “Guidance for Industry Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations, Draft Guidance”, Clinical Pharmacology, pp. 2-75, XP055667243 (2012). [cited by applicant]
Baille, “The Use of Stable Isotopes in Pharmacological Research,” [cited by applicant]
Buteau, “Deuterated Drugs: Unexpectedly Nonobvious?,” [cited by applicant]
Cassella et al., CTP-543, an Oral JAK Inhibitor, [cited by applicant]
Craiglow et al., “Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis,” J Investig Dermatol 134:2988-2990 (2014). [cited by applicant]
Craiglow et al., “Topical Ruxolitinib for the Treatment of Alopecia Universalis,” JAMA Dermatol 152(4):490-491 (2016). [cited by applicant]
CTP-543 Phase 2 Results in Patients with Moderate-to-Severe Alopecia Areata. Concert Pharmaceuticals Inc. Presentation on Sep. 3, 2019. [cited by applicant]
Delamere et al., “Interventions for alopecia areata (Review),” Cochrane Database of Sys Revs 2 (2008). [cited by applicant]
Fisher et al., “The Complexities Inherent in Attempts to Decrease Drug Clearance by Blocking Sites of CYP-Mediated Metabolism,” Curr Opin Drug Discov Devel, 9(1): 101-109 (2006). [cited by applicant]
Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” [cited by applicant]
Foster, “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,” [cited by applicant]
Fukuto et al., “Determination of the Mechanism of Demethylenation of (Methylenedioxy)phenyl Compounds by Cytochrome P450 Using Deuterium Isotope Effects,” J. Med. Chem. 34: 2871-2876, 1991. [cited by applicant]
Harris et al., “Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata,” J Amer Acad Dermatol 74(2):370-371 (Feb. 2016). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/040115, dated Nov. 18, 2022. [cited by applicant]
Jakafi® (ruxolitinib) Prescribing Information, Revised Jan. 2020 pp. 1-40. [cited by applicant]
King Brett et al: “Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata”, Journal of the American Academy of Dermatology, Mosby, Inc, US, vol. 87, … [cited by applicant]
Mackay-Wiggan et al., “Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata,” J. Clin. Invest. Insight (Sep. 22, 2016). [cited by applicant]
Ostojic et al., “Ruxolitinib: a new JAK1/2 Inhibitor that Offers Promising Options for Treatment of Myelofibrosis,” [cited by applicant]
Pieri et al., “Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia,” AJH 90(1):82-83 (2015). [cited by applicant]
Press Release “Concert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results,” Dec. 14, 2016. [cited by applicant]
Press Release “Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial,” Sep. 3, 2019 [Date Accessed: Oct. 17, 2019]. [cited by applicant]
Shi et al., “The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers,” J Clin Pharmacol 52:809-818 (2012). [cited by applicant]
Shi et al., “The pharmacokinetics, pharmacodynamics and safety of orally dosed INC18424 phosphate in healthy volunteers,” J. Clin. Pharmacol, 51:1644-1654 (2011). [cited by applicant]
Shilling et al., “Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, A Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans,” [cited by applicant]
Silvestri et al., [cited by applicant]
Vandiver et al., “Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring,” Int J Dermatol 56:833-835 (2017). [cited by applicant]
Wolen, “The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence,” J Clin Pharmacol, 26: 419-424 (1986). [cited by applicant]
Xing et al., “Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition,” Nature Med. 20: 1043-49 (2014). [cited by applicant]
Grounds of Appeal in European Opposition; European Patent Application No. 18188152.5, Jun. 26, 2024. [cited by applicant]
Petition for Inter Partes Review of Claims 1-15 of U.S. Pat. No. 9,249,149; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149), Apr. 7, 2017. [cited by applicant]
Declaration of F. Peter Guengrich; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149), Apr. 7, 2017. [cited by applicant]
Patent Owner Preliminary Response; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149), Jul. 24, 2017. [cited by applicant]
Petitioner's Request for Rehearing of U.S. Pat. No. 9,249,149; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149), Nov. 13, 2017. [cited by applicant]
Decision Denying Institution of Inter Partes Review; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149), Oct. 19, 2017. [cited by applicant]
Decision Granting Petitioner's Request for Rehearing; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149), Apr. 9, 2018. [cited by applicant]
Decision Institution of Inter Partes Review; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149), Apr. 9, 2018. [cited by applicant]
Inter Partes Review Certificate; Inter Partes Review 2017-01256 (U.S. Pat. No. 9,249,149) issued Apr. 2, 2024. [cited by applicant]
Petition for Post-Grant Review, Post Grant Review PGR2017-00034 (U.S. Pat. No. 9,662,335), Jun. 27, 2018. [cited by applicant]
Decision Denying Institution of Post-Grant Review; Post Grant Review PGR2017-00034 (U.S. Pat. No. 9,662,335), Jan. 11, 2018. [cited by applicant]
Federal Circuit Decision in [cited by applicant]